The purpose of the AASLD/EASL HBV Endpoints Conference is to bring together the academic, regulatory, pharmaceutical communities and patients’ advocacy groups to discuss therapeutic endpoints, trial designs appropriate patient populations and safety concerns with regards to novel therapeutic approaches for treatment of chronic hepatitis B and D. The HBV therapeutic field is at a crossroads with many different approaches being considered but numerous regulatory issues, trial design issues and safety issues need to be addressed. This meeting will be unique in that it will bring all the important and relevant parties to the table to discuss these critical issues that will need to be resolved before substantial progress can be made in delivering the next generation of therapeutic agents to affected individuals with chronic hepatitis B and D.